Want to see BLRX full AI Analyst Report?
BLRX Stock Chart & Stats
$2.76
$0.05(1.77%)
At close: 4:00 PM EDT
$2.76
$0.05(1.77%)
Day’s Range― - ―
52-Week Range$2.15 - $4.56
Previous CloseN/A
Volume257.00
Average Volume (3M)19.99K
Market Cap
$13.52M
Enterprise Value$11.57
Total Cash (Recent Filing)$13.08M
Total Debt (Recent Filing)$7.94M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Nov 18, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding4,848,991
10 Day Avg. Volume43,804
30 Day Avg. Volume19,990
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.63
Price to Sales (P/S)9.57
P/FCF Ratio-1.39
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$26.00Price Target Upside842.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)$1.95M
Bulls Say, Bears Say
Bulls Say
GLIX1 Clinical ProgressRapid enrollment and reported early safety and tolerability reduce execution risk for GLIX1’s development program. Progress across multiple clinical sites supports timely Phase I data and could create a foundation for broader oncology development if the asset continues to validate clinically.
Differentiated Oncology PipelineA differentiated mechanism, central nervous system penetration, and activity in treatment-resistant models give GLIX1 potential relevance in cancers with substantial unmet need. These attributes may support durable development value and combination opportunities beyond the initial indication.
Commercial Product And Royalty BaseAPHEXDA provides BiolineRx with an approved commercial asset and an established royalty-generating pathway alongside its clinical pipeline. Even at an early revenue level, this creates a nonclinical foundation that can diversify funding sources and support future milestone or royalty growth.
Bears Say
Deep And Persistent LossesOperating expenses currently overwhelm gross profit, leaving the company deeply loss-making despite a roughly 70% gross margin. Continued negative earnings weaken internal funding capacity and make successful clinical or commercial execution increasingly important to long-term financial sustainability.
Ongoing Cash BurnBiolineRx is not self-funding operations, so continued research, commercialization, and clinical development depend on available cash, royalties, milestones, or new capital. Persistent burn reduces financial flexibility and increases the importance of achieving meaningful pipeline or product revenue.
APHEXDA Adoption ChallengesThe approved product has yet to demonstrate strong revenue scale, and adoption depends on changing established transplant-center protocols amid generic competition. Slow uptake could limit near-term commercial contribution, leaving BiolineRx reliant on uncertain pipeline progress and partnership economics.
Bioline RX Ltd Sponsored ADR News
BLRX FAQ
What was Bioline RX Ltd Sponsored ADR’s price range in the past 12 months?
Bioline RX Ltd Sponsored ADR lowest stock price was $2.15 and its highest was $4.56 in the past 12 months.
What is Bioline RX Ltd Sponsored ADR’s market cap?
Bioline RX Ltd Sponsored ADR’s market cap is $13.52M.
When is Bioline RX Ltd Sponsored ADR’s upcoming earnings report date?
Bioline RX Ltd Sponsored ADR’s upcoming earnings report date is Nov 18, 2026 which is in 72 days.
How were Bioline RX Ltd Sponsored ADR’s earnings last quarter?
Bioline RX Ltd Sponsored ADR released its earnings results on Aug 31, 2026. The company reported $0 earnings per share for the quarter.
Is Bioline RX Ltd Sponsored ADR overvalued?
According to Wall Street analysts Bioline RX Ltd Sponsored ADR’s price is currently Undervalued.
Does Bioline RX Ltd Sponsored ADR pay dividends?
Bioline RX Ltd Sponsored ADR does not currently pay dividends.
What is Bioline RX Ltd Sponsored ADR’s EPS estimate?
Bioline RX Ltd Sponsored ADR’s EPS estimate is -0.39.
How many shares outstanding does Bioline RX Ltd Sponsored ADR have?
Bioline RX Ltd Sponsored ADR has 4,848,991 shares outstanding.
What happened to Bioline RX Ltd Sponsored ADR’s price movement after its last earnings report?
Bioline RX Ltd Sponsored ADR reported an EPS of $0 in its last earnings report. Following the earnings report the stock price went up 7.692%.
Which hedge fund is a major shareholder of Bioline RX Ltd Sponsored ADR?
Currently, no hedge funds are holding shares in BLRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioline RX Ltd Sponsored ADR
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
BLRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive, driven by strong GLIX1 clinical enrollment and early safety and tolerability, encouraging glioblastoma and ovarian-cancer preclinical results, continued PDAC trial enrollment, APHEXDA royalty generation, and a cash runway extending into the first half of 2027. Offsetting points included a higher quarterly net loss, flat revenue, uncertainty around the evolving PDAC treatment landscape, and the substantial work still required to expand APHEXDA adoption.View all BLRX earnings summariesBLRX Stock 12 Month Forecast
Average Price Target
$26.00
▲(842.03% Upside)
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors